Dr Reddys Laboratories (RDY) Share-based Compensation (2009)
Dr Reddys Laboratories (RDY) posted quarterly Share-based Compensation of $2.0 million for Q4 2009, up 100.0% on a QoQ basis from $1.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Share-based Compensation (2009) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Share-based Compensation for 1 consecutive years, with $2.0 million the latest figure, recorded in Q4 2009.
- Quarterly Share-based Compensation changed N/A year-over-year to $2.0 million in Q4 2009, while the trailing twelve-month figure through Dec 2009 was $5.5 million (changed N/A YoY) and the FY2026 annual result came in at $3.0 million, down 40.0% from the prior year.
- Share-based Compensation climbed to $2.0 million in Q4 2009 per RDY's latest filing, from $1.0 million in the prior quarter.
- Over the last five years, Share-based Compensation for RDY reached as high as $2.0 million in Q4 2009 and fell as low as $1.0 million in Q2 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | 2.00 Mn |
| Dec 31, 2009 | 2.00 Mn |
| Sep 30, 2009 | 1.00 Mn |
| Sep 30, 2009 | 1.00 Mn |
| Jun 30, 2009 | 1.00 Mn |
| Jun 30, 2009 | 1.00 Mn |